Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635531 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00635531 is a Phase 4 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 16 participants.
The verdict
NCT00635531, a Phase 4 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder
Interventions
- OTHER placebo
- DRUG alprazolam XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635531
The ClinicalTrials.gov registry entry for NCT00635531 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00635531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635531 about?
NCT00635531 is a clinical study titled "A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder". The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder
What is the current status of trial NCT00635531?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2004-04. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00635531?
The interventions under investigation include: placebo (OTHER), alprazolam XR (DRUG).
Who is sponsoring clinical trial NCT00635531?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.